Welcome to LookChem.com Sign In|Join Free
  • or
Pyridine, 3-[5-[4-[(3,7-dimethyl-2,6-octadienyl)oxy]phenyl]-2-oxazolyl]- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

89764-17-0

Post Buying Request

89764-17-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

89764-17-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 89764-17-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,7,6 and 4 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 89764-17:
(7*8)+(6*9)+(5*7)+(4*6)+(3*4)+(2*1)+(1*7)=190
190 % 10 = 0
So 89764-17-0 is a valid CAS Registry Number.

89764-17-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-[4-(3,7-dimethylocta-2,6-dienoxy)phenyl]-2-pyridin-3-yl-1,3-oxazole

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:89764-17-0 SDS

89764-17-0Downstream Products

89764-17-0Relevant academic research and scientific papers

Structure-Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells

Robles, Andrew J.,McCowen, Shelby,Cai, Shengxin,Glassman, Michaels,Ruiz, Francisco,Cichewicz, Robert H.,McHardy, Stanton F.,Mooberry, Susan L.

, p. 9275 - 9289 (2017/11/30)

Targeted therapies for ER+/PR+ and HER2-amplified breast cancers have improved patient survival, but there are no therapies for triple negative breast cancers (TNBC) that lack expression of estrogen and progesterone receptors (ER/PR), or amplification or

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 89764-17-0